These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21929536)

  • 1. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
    Laws PM; Downs AM; Parslew R; Dever B; Smith CH; Barker JN; Moriarty B; Murphy R; Kirby B; Burden AD; McBride S; Anstey AV; O'Shea S; Ralph N; Buckley C; Griffiths CE; Warren RB
    Br J Dermatol; 2012 Jan; 166(1):189-95. PubMed ID: 21929536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
    Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
    Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
    Feldman SR; Zhao Y; Gilloteau I; Graham CN; Miles L; McBride D; Herrera V
    J Manag Care Spec Pharm; 2018 Jul; 24(7):617-622. PubMed ID: 29952701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
    Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
    Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.